Ofatumumab - Genmab/GlaxoSmithKline/Novartis

Drug Profile

Ofatumumab - Genmab/GlaxoSmithKline/Novartis

Alternative Names: Anti-CD20 monoclonal antibody - Genmab; Anti-CD20-monoclonal-antibody-GlaxoSmithKline; Arzerra; GSK-1841157; HuMax CD20; OMB-157

Latest Information Update: 11 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab
  • Developer Genmab; GlaxoSmithKline; Mundipharma International; National Cancer Centre (Singapore); Novartis; Roswell Park Cancer Institute; University Health Network
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Phase III B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple sclerosis
  • Phase II Marginal-zone-B-cell-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Suspended Neuromyelitis optica
  • Discontinued Pemphigus vulgaris; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 27 Jun 2018 Novartis plans a phase II trial for Multiple sclerosis (SC) (NCT03560739)
  • 24 May 2018 Novartis Pharmaceuticals completes the phase III COMPLEMENT A+B trial for B-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA, Argentina, Austria, Belgium, Brazil, Canada, France, Germany, Greece, Hong Kong, Italy, Japan, Poland, Puerto Rico, Russia, Slovakia, Ukraine, United Kingdom (IV) before May 2018
  • 10 May 2018 GlaxoSmithKline and Novartis terminates a phase I trial for Chronic lymphocytic leukaemia and B-cell lymphoma (combination therapy, second line therapy or greater) in USA due to insufficient accrual (NCT01352312)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top